search
Back to results

Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Ibuprofen
Sponsored by
Swiss Federal Institute of Technology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Obesity focused on measuring Iron bioavailability, Inflammation, Hepcidin, Iron absorption

Eligibility Criteria

18 Years - 45 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2)
  • pre-menopausal
  • no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity
  • no-smoking

Exclusion Criteria:

  • Diagnosed chronic disease or gastrointestinal disorders
  • Metabolic disorders (e.g. diabetes)
  • Regular use of medication (except oral contraceptives)
  • Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study
  • Pregnancy or lactation

Sites / Locations

  • Human Nutrition Laboratory ETH Zurich

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

normal-weight

obesity

Arm Description

normal-weight women

obese women

Outcomes

Primary Outcome Measures

Fractional iron absorption
The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals. Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic. The investigators assumed iron incorporation into erythrocytes to be constant. Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.

Secondary Outcome Measures

Plasma ferritin
Hemoglobin
Transferrin receptor
Hepcidin
c-reactive protein
interleukin-6
alpha-1-acid-glycoprotein

Full Information

First Posted
April 18, 2016
Last Updated
October 3, 2019
Sponsor
Swiss Federal Institute of Technology
Collaborators
University of Monterrey, Mexico
search

1. Study Identification

Unique Protocol Identification Number
NCT02745925
Brief Title
Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation
Official Title
Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 2016 (Actual)
Primary Completion Date
December 2018 (Actual)
Study Completion Date
December 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Swiss Federal Institute of Technology
Collaborators
University of Monterrey, Mexico

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The main iron regulatory protein in the human metabolism is hepcidin. In normal weight, healthy subjects, hepcidin is regulated through the iron status of the body: low iron status results in low hepcidin concentrations, which facilitates dietary iron absorption. In obesity, which is an inflammatory state, hepcidin concentrations are increased and iron absorption is reduced despite low iron stores, leading to iron deficiency over time. Whether lowering the chronic low-grade inflammation during a limited treatment period and thereby lowering hepcidin concentration can improve iron absorption is uncertain.
Detailed Description
In states of high hepcidin concentration, intestinal iron absorption (through enterocytes) and recycling of iron (through macrophages) is reduced. The extent to which non-heme iron is absorbed from the diet is influenced by the composition of the diet. Ascorbic acid is a potent enhancer of non-heme iron absorption. It's mechanism of action is luminal reduction of dietary ferric iron (Fe3+) to more soluble ferrous iron (Fe2+). A study in the inestigator's laboratory showed that the enhancing effect of ascorbic acid on non-heme iron absorption is reduced in overweight and obese individuals. Possible explanations for this fact are the different sites of action of ascorbic acid and serum hepcidin on the enterocytes in dietary iron absorption. Increased hepcidin reduces iron efflux into the circulation at the basolateral membrane of the enterocyte. Therefore the improved iron transport into enterocytes through ascorbic acid at the luminal side (via the divalent metal transporter (DMT)-1), by reducing Fe3+ to Fe2+ seems to be less successful. To improve iron absorption in obese subjects, an intervention at the basolateral membrane of the enterocyte would be needed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Iron bioavailability, Inflammation, Hepcidin, Iron absorption

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
normal-weight
Arm Type
Experimental
Arm Description
normal-weight women
Arm Title
obesity
Arm Type
Experimental
Arm Description
obese women
Intervention Type
Drug
Intervention Name(s)
Ibuprofen
Primary Outcome Measure Information:
Title
Fractional iron absorption
Description
The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals. Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic. The investigators assumed iron incorporation into erythrocytes to be constant. Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.
Time Frame
Days 15 and 45
Secondary Outcome Measure Information:
Title
Plasma ferritin
Time Frame
Days 1, 15, 30, 45
Title
Hemoglobin
Time Frame
Days 1, 15, 30, 45
Title
Transferrin receptor
Time Frame
Days 1, 15, 30, 45
Title
Hepcidin
Time Frame
Days 1, 15, 30, 45
Title
c-reactive protein
Time Frame
Days 1, 15, 30, 45
Title
interleukin-6
Time Frame
Days 1, 15, 30, 45
Title
alpha-1-acid-glycoprotein
Time Frame
Days 1, 15, 30, 45

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2) pre-menopausal no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity no-smoking Exclusion Criteria: Diagnosed chronic disease or gastrointestinal disorders Metabolic disorders (e.g. diabetes) Regular use of medication (except oral contraceptives) Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study Pregnancy or lactation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Isabelle Herter-Aeberli, PhD
Organizational Affiliation
University of Zurich
Official's Role
Principal Investigator
Facility Information:
Facility Name
Human Nutrition Laboratory ETH Zurich
City
Zurich
ZIP/Postal Code
8092
Country
Switzerland

12. IPD Sharing Statement

Learn more about this trial

Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation

We'll reach out to this number within 24 hrs